Why the study?
Following the approval of idarucizumab and andexanet alfa, questions remain regarding whether specific antidotes fulfill an unmet need and improve outcomes in DOAC-treated patients.
The availability of specific antidotes like idarucizumab and andexanet alfa improves the safety profile of DOACs by allowing rapid reversal during life-threatening bleeding or urgent procedures.
May support urgent DOAC reversal with specific antidotes; leaves open need for randomized trials to guide practice.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Godiér et al. (2019) conducted an editorial in Direct oral anticoagulant reversal. Direct oral anticoagulant antidotes (idarucizumab, andexanet alfa) was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: